Quantbot Technologies
TCRR

Quantbot Technologies’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Quantbot Technologies’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-800
Closed -$2K – 2276
2022
Q1 		$2K Sell
800
-8,000
-91% -$25.2K ﹤0.01% 1574
2021
Q4 		$41K Buy
8,800
+5,500
+167% +$34.4K ﹤0.01% 1082
2021
Q3 		$28K Buy
+3,300
New +$46.6K ﹤0.01% 1217

Other funds holding TCRR

MPM Asset Management
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Tang Capital Management
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
MPM BioImpact
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Redmile Group
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Quantbot Technologies's TCRR Position: Q2 2022 in Review

Quantbot Technologies sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2022, closing a stake of 800 shares — an estimated $2K sold.

Quantbot Technologies first reported a position in TCRR in Q3 2021 and held it in 3 quarters. The position peaked at $41K in Q4 2021. 83 funds tracked by Wall St. Rank hold TCRR as of Q2 2022.

  • Quantbot Technologies reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Quantbot Technologies sold 800 TCR2 Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $2K.
  • Quantbot Technologies first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2021 and held it in 3 quarters.
  • Quantbot Technologies's TCR2 Therapeutics Inc. Common Stock position peaked at $41K in Q4 2021.
  • 83 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2022.

Based on Quantbot Technologies's 13F filing for Q2 2022, filed 9 Aug 2022.